Cargando…

Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer

BACKGROUND: Biliary tract cancer (BTC) is an uncommon but highly lethal malignancy with poor clinical outcomes. To promote the development of precision medicine for BTC, uncovering its genomic profile becomes particularly important. However, studies on the genomic feature of Chinese BTC patients rem...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Haipeng, Xu, Yan, Gao, Wei, Li, Mei, He, Ji’an, Deng, Xiaoqian, Xing, Wenge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441936/
https://www.ncbi.nlm.nih.gov/pubmed/36072793
http://dx.doi.org/10.3389/fonc.2022.930611
_version_ 1784782700194824192
author Yu, Haipeng
Xu, Yan
Gao, Wei
Li, Mei
He, Ji’an
Deng, Xiaoqian
Xing, Wenge
author_facet Yu, Haipeng
Xu, Yan
Gao, Wei
Li, Mei
He, Ji’an
Deng, Xiaoqian
Xing, Wenge
author_sort Yu, Haipeng
collection PubMed
description BACKGROUND: Biliary tract cancer (BTC) is an uncommon but highly lethal malignancy with poor clinical outcomes. To promote the development of precision medicine for BTC, uncovering its genomic profile becomes particularly important. However, studies on the genomic feature of Chinese BTC patients remain insufficient. METHODS: A total of 382 Chinese patients with BTC were enrolled in this study, including 71 with intrahepatic cholangiocarcinoma (ICC), 194 with extrahepatic cholangiocarcinoma (ECC), and 117 with gallbladder carcinoma (GBC). Genetic testing was performed by utilizing the next-generation sequencing (NGS) of 499 cancer-related genes and the results were compared to those of Western BTC patients (MSKCC cohorts). RESULTS: The most prevalent genes were TP53 (51.6%), ARID1A (25.9%), KMT2C (24.6%), NCOR1 (17%), SMAD4 (15.2%), KRAS (14.9%), KMT2D (14.9%), ATM (14.1%), and APC (13.9%) in Chinese BTC patients. TP53, SMAD4, and APC were more prevalent in GBC, ECC, and ICC, respectively. In addition, 10.5% of Chinese BTC patients harbored pathogenic or likely pathogenic (P/LP) germline alterations in 41 genes, which were mainly related to DNA damage repair (DDR). Additionally, the genomic features of Chinese and Western BTC tumors were similar, with the exception of the notable difference in the prevalence of TP53, KRAS, IDH1, KMT2C, and SMAD4. Notably, Chinese BTC patients had high prevalence (57.1%) of actionable alterations, especially for those with ECC, and half (192/382) of them had somatic DDR alterations, with the prevalence of deleterious ones being significantly higher than their Western counterparts. Twenty-three percent of patients had a higher tumor mutational burden (TMB-H, over 10 mutations/MB), and TMB was significantly higher in those with deleterious DDR alterations and/or microsatellite instability-high. The most common mutational signature in BTC patients was Signature 1, and interestingly, Signatures 1, 4, and 26 were significantly associated with higher TMB level, but not with the survival of patients who had received immunotherapy in pan-cancer. CONCLUSION: Our study elaborated the distinct germline and somatic genomic characteristics of Chinese BTC patients and identified clinically actionable alterations, highlighting the possibility for the development and application of precision medicine.
format Online
Article
Text
id pubmed-9441936
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94419362022-09-06 Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer Yu, Haipeng Xu, Yan Gao, Wei Li, Mei He, Ji’an Deng, Xiaoqian Xing, Wenge Front Oncol Oncology BACKGROUND: Biliary tract cancer (BTC) is an uncommon but highly lethal malignancy with poor clinical outcomes. To promote the development of precision medicine for BTC, uncovering its genomic profile becomes particularly important. However, studies on the genomic feature of Chinese BTC patients remain insufficient. METHODS: A total of 382 Chinese patients with BTC were enrolled in this study, including 71 with intrahepatic cholangiocarcinoma (ICC), 194 with extrahepatic cholangiocarcinoma (ECC), and 117 with gallbladder carcinoma (GBC). Genetic testing was performed by utilizing the next-generation sequencing (NGS) of 499 cancer-related genes and the results were compared to those of Western BTC patients (MSKCC cohorts). RESULTS: The most prevalent genes were TP53 (51.6%), ARID1A (25.9%), KMT2C (24.6%), NCOR1 (17%), SMAD4 (15.2%), KRAS (14.9%), KMT2D (14.9%), ATM (14.1%), and APC (13.9%) in Chinese BTC patients. TP53, SMAD4, and APC were more prevalent in GBC, ECC, and ICC, respectively. In addition, 10.5% of Chinese BTC patients harbored pathogenic or likely pathogenic (P/LP) germline alterations in 41 genes, which were mainly related to DNA damage repair (DDR). Additionally, the genomic features of Chinese and Western BTC tumors were similar, with the exception of the notable difference in the prevalence of TP53, KRAS, IDH1, KMT2C, and SMAD4. Notably, Chinese BTC patients had high prevalence (57.1%) of actionable alterations, especially for those with ECC, and half (192/382) of them had somatic DDR alterations, with the prevalence of deleterious ones being significantly higher than their Western counterparts. Twenty-three percent of patients had a higher tumor mutational burden (TMB-H, over 10 mutations/MB), and TMB was significantly higher in those with deleterious DDR alterations and/or microsatellite instability-high. The most common mutational signature in BTC patients was Signature 1, and interestingly, Signatures 1, 4, and 26 were significantly associated with higher TMB level, but not with the survival of patients who had received immunotherapy in pan-cancer. CONCLUSION: Our study elaborated the distinct germline and somatic genomic characteristics of Chinese BTC patients and identified clinically actionable alterations, highlighting the possibility for the development and application of precision medicine. Frontiers Media S.A. 2022-08-22 /pmc/articles/PMC9441936/ /pubmed/36072793 http://dx.doi.org/10.3389/fonc.2022.930611 Text en Copyright © 2022 Yu, Xu, Gao, Li, He, Deng and Xing https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yu, Haipeng
Xu, Yan
Gao, Wei
Li, Mei
He, Ji’an
Deng, Xiaoqian
Xing, Wenge
Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer
title Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer
title_full Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer
title_fullStr Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer
title_full_unstemmed Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer
title_short Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer
title_sort comprehensive germline and somatic genomic profiles of chinese patients with biliary tract cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441936/
https://www.ncbi.nlm.nih.gov/pubmed/36072793
http://dx.doi.org/10.3389/fonc.2022.930611
work_keys_str_mv AT yuhaipeng comprehensivegermlineandsomaticgenomicprofilesofchinesepatientswithbiliarytractcancer
AT xuyan comprehensivegermlineandsomaticgenomicprofilesofchinesepatientswithbiliarytractcancer
AT gaowei comprehensivegermlineandsomaticgenomicprofilesofchinesepatientswithbiliarytractcancer
AT limei comprehensivegermlineandsomaticgenomicprofilesofchinesepatientswithbiliarytractcancer
AT hejian comprehensivegermlineandsomaticgenomicprofilesofchinesepatientswithbiliarytractcancer
AT dengxiaoqian comprehensivegermlineandsomaticgenomicprofilesofchinesepatientswithbiliarytractcancer
AT xingwenge comprehensivegermlineandsomaticgenomicprofilesofchinesepatientswithbiliarytractcancer